#4 - AbbVie (NYSE:ABBV)
AbbVie Inc. (NYSE: ABBV) is a well-established dividend payer with a strong track record of annual increases since becoming an independent company in 2013. AbbVie has raised its dividend every year since its spin-off from Abbott Laboratories, which itself is a Dividend King with over 50 consecutive years of dividend growth. The current dividend yield is approximately 3.4%, and the company has increased its payout by an average of over 6% annually over the past three years.
The company is perhaps best known for its blockbuster drug, Humira. In 2024, AbbVie navigated through a year in which Humira faced biosimilar competition for the first time. Despite this, AbbVie generated approximately $11 billion in revenue from Humira that year—a sharp decline from prior years but still a strong figure compared to historical performance.
The biopharmaceutical sector can be challenging for investors to navigate, but AbbVie remains a compelling name due to its diversified portfolio and promising pipeline. Newer immunology drugs, such as Skyrizi and Rinvoq, have seen robust growth and are expected to be key drivers of future revenue and earnings growth.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
More- Current Price
- $193.20
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 19 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $208.35 (7.8% Upside)
